Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Change in Accured Expenses (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Change in Accured Expenses for 5 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 252.26% to -$3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.5 million through Dec 2025, down 317.02% year-over-year, with the annual reading at -$7.5 million for FY2025, 317.02% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$3.9 million at Werewolf Therapeutics, down from -$1.2 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $5.3 million in Q4 2021, with the low at -$3.9 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is -$3833.3, with a median of $520000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses tumbled 2152.36% in 2023, then skyrocketed 171.88% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $5.3 million in 2021, then crashed by 130.81% to -$1.6 million in 2022, then surged by 158.43% to $953000.0 in 2023, then soared by 171.88% to $2.6 million in 2024, then tumbled by 252.26% to -$3.9 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$3.9 million, -$1.2 million, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.